莫西沙星联合舒利迭吸入对慢性阻塞性肺疾病急性加重期患者血清SAA TGF-β1 copeptin sICAM-1的影响  

Effects of Moxifloxacin Combined Seretide on Serum SAA TGF-β1 Copeptin,and sICAM-1 of AEC OPD

作　　者：于晴[1] 王靖賾 YU Qing;WANG Jingze(Chifeng Hospital,Inner Mongolia Chifeng 024000,China)

机构地区：[1]内蒙古赤峰市医院重症医学科,内蒙古赤峰024000 [2]内蒙古赤峰市松山医院重症医学科,内蒙古赤峰024000

出　　处：《河北医学》2018年第6期905-908,共4页Hebei Medicine

基　　金：内蒙古自然科学基金项目;(编号:2013MS1116)

摘　　要：目的:研究莫西沙星联合舒利迭吸入疗法在慢性阻塞性肺疾病急性发作(AECOPD)时的临床疗效,及其对血清淀粉样蛋白A(SAA)、转化生长因子-β1(TGF-β1)、和素肽(copeptin)、可溶性细胞间黏附因子-1(sICAM-1)的影响。方法:本实验选取我院2015年12月至2016年12月收治的102例AECOPD病患为研究对象,随机分为对照组及实验组,每组51例。对照组在接受常规治疗的基础上予舒利迭联合阿莫西林-克拉维酸吸入治疗,实验组基于对照组基础治疗加上莫西沙星联合舒利迭吸入治疗。比较两组临床疗效,观察血清SAA,TGF-β1,copeptin,sICAM-1水平变化,动脉血血气分析二氧化碳分压(PaCO_2)及氧分压(PaO_2),检测肺功能:第1秒用力呼气容积(FEV1)、肺活量(FVC)及FEV1/FVC,评估COPD患者生存质量及呼吸困难程度:改良呼吸困难评分(Medical Research Council Dyspnoea Scale,m MRC)、慢阻肺评估测试(COPD Assessment Test,CAT),和发生不良反应的情况。结果:治疗后,实验组有效率(92.16%)显著高于对照组,差异有统计学意义(P<0.05)。两组肺功能检测:FEV1、FCV、FEV1/FCV,治疗后均有所改善,差异有统计学意义(P<0.05),且实验组较对照组改善更多(P<0.05)。两组动脉血气分析比较,治疗后,PaO_2有明显上升(P<0.05),且实验组高于对照组,差异均有统计学意义(P<0.05)。治疗前后两组患者生存质量及呼吸困难分级评估,治疗后均明显改善,差异有统计学意义(P<0.05),且实验组明显低于对照组(P<0.05),差异有统计学意义。两组不良反应比较无差异(P>0.05)。结论:莫西沙星联合舒利迭吸入对AECOPD患者的临床疗效肯定,能够降低血清SAA、TGF-β1、copeptin、sICAM-1浓度,改善动脉血氧分压、患者生存质量及肺功能。Objective： To study the clinical efficacy of moxifloxacin combined seretide inhalation in acute exacerbation of chronic obstructive pulmonary disease（ AECOPD）,and its effects on serum amyloid A（ SAA）,transforming growth factor-β1（ TGF-β1）,copeptin,soluble intercellular adhesion factor-1（ sICAM-1）. Methods： A total of 102 AECOPD patients were enrolled of our hospital from December 2015 to December 2016. They were randomly divided into control group and experimental group（ n = 51）. The control group was treated with seretide combined Amoxicillin-clavulanic acid inhalation on the basis of routine treatment. The experimental group was treated with moxifloxacin combined seretide inhalation. To compare the changes of serum SAA,TGF-β1,copeptin and sICAM-1 in two groups,to observe the changes of serum CO_2 A（ PaCO_2） and oxygen partial pressure（ PaO_2）,and to detect lung function：（ FEV1）,vital capacity（ FVC） and FEV1/FVC were used to assess the quality of life and dyspnea of patients with COPD： Medical Research Council Dyspnoea Scale（ m MRC）,COPD Assessment Test（ CAT）,and adverse events. Results：After treatment,the effective rate（ 92.16%） in the experimental group was significantly higher than that in the control group（ P〈0.05）. FEV1,FCV,FEV1/FCV were improved after treatment,the difference was statistically significant（ P〈0.05）,and the experimental group improved more than the control group（ P〈0.05）.Compared with the control group,the difference was statistically significant（ P〈0.05）. The PaO_2 of the two groups was significantly higher than that of the control group（ P〈0.05）.,and the experimental group was significantly lower than the control group（ P〈0.05）,the difference was statistically significant（ P〈0.05）,and the difference was statistically significant（ P〈0. 05）. There was no significant difference between the two groups（ P〉0.05）. Conclusion： The clinical efficacy of moxifloxacin combined seretide

关 键 词：慢性阻塞性肺疾病 急性加重期 莫西沙星 舒利迭 

分 类 号：R563.9[医药卫生—呼吸系统]